Luciana Molinero

5PUBLICATIONS
44CO-AUTHORS
Predictive and prognostic markersMolecular targetsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Mar 25, 2024
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy.

Xiao Li, Jeffrey Eastham, Jennifer M Giltnane

|Jan 03, 2023
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.

Charles N Landen, Luciana Molinero, Habib Hamidi

|Jun 30, 2022
PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers.

Ethan S Sokol, Dexter X Jin, Alexander Fine

|Apr 23, 2021
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).

Kathleen N Moore, Michael Bookman, Jalid Sehouli

|Feb 24, 2016
Cutting Edge: Engineering Active IKKβ in T Cells Drives Tumor Rejection.

César Evaristo, Stefani Spranger, Sarah E Barnes

Pageof 1

Frequent Collaborators

2 joint publications

Kathleen N Moore

2 joint publications

Michael Bookman

2 joint publications

Tashanna Myers

2 joint publications

Sandro Pignata